BIOCHAPERONE® GLARGINE GLP-1
BIOCHAPERONE® GLARGINE GLP-1: a simple intensification option over basal insulin
Basal insulin remains an essential treatment for patients with type 2 diabetes who do not reach glycemic targets on oral antidiabetic agents. However, by some estimates, up to 50% of people with diabetes who use basal insulin as their only injectable treatment do not reach their glycemic target1.
To address the need for intensification of treatment from basal insulin alone or GLP-1 alone, Adocia initiated a preclinical BioChaperone program in the preclinical stage, combining basal insulin (insulin glargine) with GLP-1 receptor agonists (“GLP1”, eg liraglutide). This program takes advantage of Adocia’s expertise in the solubilization of insulin glargine at physiological pH.
1 Sanofi, Corporate presentation Q3 2015